JP2010534243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534243A5 JP2010534243A5 JP2010518230A JP2010518230A JP2010534243A5 JP 2010534243 A5 JP2010534243 A5 JP 2010534243A5 JP 2010518230 A JP2010518230 A JP 2010518230A JP 2010518230 A JP2010518230 A JP 2010518230A JP 2010534243 A5 JP2010534243 A5 JP 2010534243A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- agent
- antibody
- item
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 20
- 102000036639 antigens Human genes 0.000 claims description 20
- 108091007433 antigens Proteins 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 20
- 206010052779 Transplant rejections Diseases 0.000 claims description 14
- 239000003018 immunosuppressive agent Substances 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 230000028993 immune response Effects 0.000 claims description 11
- 229960003444 immunosuppressant agent Drugs 0.000 claims description 11
- 230000001861 immunosuppressant effect Effects 0.000 claims description 11
- 239000002955 immunomodulating agent Substances 0.000 claims description 10
- 229940121354 immunomodulator Drugs 0.000 claims description 10
- 230000002584 immunomodulator Effects 0.000 claims description 10
- 210000000056 organ Anatomy 0.000 claims description 10
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims description 8
- 229930105110 Cyclosporin A Natural products 0.000 claims description 8
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 8
- 108010036949 Cyclosporine Proteins 0.000 claims description 8
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims description 8
- 229960001265 ciclosporin Drugs 0.000 claims description 8
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 8
- 229960002930 sirolimus Drugs 0.000 claims description 8
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 230000003993 interaction Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 230000004044 response Effects 0.000 claims description 6
- 230000004083 survival effect Effects 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229940122739 Calcineurin inhibitor Drugs 0.000 claims description 4
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 claims description 4
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 102000006395 Globulins Human genes 0.000 claims description 4
- 108010044091 Globulins Proteins 0.000 claims description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000007774 longterm Effects 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 3
- 230000000735 allogeneic effect Effects 0.000 claims description 3
- 238000011316 allogeneic transplantation Methods 0.000 claims description 3
- 230000002519 immonomodulatory effect Effects 0.000 claims description 3
- 238000002689 xenotransplantation Methods 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- 230000006978 adaptation Effects 0.000 claims description 2
- 229940009456 adriamycin Drugs 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 230000001494 anti-thymocyte effect Effects 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
- 229960002170 azathioprine Drugs 0.000 claims description 2
- 229960004669 basiliximab Drugs 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims description 2
- 229960002092 busulfan Drugs 0.000 claims description 2
- 229960004397 cyclophosphamide Drugs 0.000 claims description 2
- 229960002806 daclizumab Drugs 0.000 claims description 2
- 229960000390 fludarabine Drugs 0.000 claims description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 230000008348 humoral response Effects 0.000 claims description 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 2
- 210000004153 islets of langerhan Anatomy 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- 229960003816 muromonab-cd3 Drugs 0.000 claims description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000008629 immune suppression Effects 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000012177 negative regulation of immune response Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 44
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US96202207P | 2007-07-25 | 2007-07-25 | |
| PCT/US2008/009037 WO2009014745A1 (en) | 2007-07-25 | 2008-07-25 | Antibodies to cd200 and uses thereof in inhibiting immune responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013110577A Division JP5926702B2 (ja) | 2007-07-25 | 2013-05-27 | Ｃｄ２００に対する抗体および免疫応答への使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534243A JP2010534243A (ja) | 2010-11-04 |
| JP2010534243A5 true JP2010534243A5 (https=) | 2012-07-05 |
Family
ID=40001380
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010518230A Pending JP2010534243A (ja) | 2007-07-25 | 2008-07-25 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2013110577A Expired - Fee Related JP5926702B2 (ja) | 2007-07-25 | 2013-05-27 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2015135830A Pending JP2015172090A (ja) | 2007-07-25 | 2015-07-07 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2016052050A Pending JP2016117762A (ja) | 2007-07-25 | 2016-03-16 | Ｃｄ２００に対する抗体および免疫応答への使用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013110577A Expired - Fee Related JP5926702B2 (ja) | 2007-07-25 | 2013-05-27 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2015135830A Pending JP2015172090A (ja) | 2007-07-25 | 2015-07-07 | Ｃｄ２００に対する抗体および免疫応答への使用 |
| JP2016052050A Pending JP2016117762A (ja) | 2007-07-25 | 2016-03-16 | Ｃｄ２００に対する抗体および免疫応答への使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | USRE46323E1 (https=) |
| EP (1) | EP2178561A1 (https=) |
| JP (4) | JP2010534243A (https=) |
| KR (1) | KR20100041849A (https=) |
| AU (1) | AU2008279619B2 (https=) |
| BR (1) | BRPI0814644A2 (https=) |
| CA (1) | CA2697159C (https=) |
| MX (1) | MX2010000981A (https=) |
| WO (1) | WO2009014745A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009014745A1 (en) * | 2007-07-25 | 2009-01-29 | Alexion Pharmaceuticals, Inc. | Antibodies to cd200 and uses thereof in inhibiting immune responses |
| KR20130036192A (ko) * | 2010-02-11 | 2013-04-11 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-ｃｄ200 항체들을 이용한 치료 및 진단 방법 |
| WO2012106634A1 (en) | 2011-02-03 | 2012-08-09 | Alexion Pharmaceuticals, Inc. | Use of an anti-cd200 antibody for prolonging the survival of allografts |
| ES2785349T3 (es) | 2011-06-10 | 2020-10-06 | Canada Minister Nat Defence | Anticuerpos anti-ricina y sus usos |
| EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| US9737598B2 (en) | 2014-06-30 | 2017-08-22 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| CA2969384A1 (en) * | 2014-12-17 | 2016-06-23 | Cellectis | Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain |
| AU2016349897B2 (en) | 2015-11-03 | 2021-11-04 | Regents Of The University Of Minnesota | CD200 inhibitors and methods of use thereof |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| WO2018102594A1 (en) * | 2016-12-01 | 2018-06-07 | Alexion Pharmaceuticals, Inc. | Methods of treating solid tumors with anti-cd200 antibodies |
| KR101968246B1 (ko) * | 2017-04-27 | 2019-04-11 | 서울대학교산학협력단 | 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법 |
| US11761963B2 (en) | 2017-09-27 | 2023-09-19 | Alexion Pharmaceuticals, Inc. | Biomarker signature for predicting tumor response to anti-CD200 therapy |
| WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
| WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
| WO2020150149A1 (en) | 2019-01-14 | 2020-07-23 | Regents Of The University Of Minnesota | Cd200ar ligands for cancer immunotherapy |
| EP4296280A1 (en) | 2022-06-21 | 2023-12-27 | F. Hoffmann-La Roche AG | Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7223729B2 (en) | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
| EP1032662B1 (en) * | 1997-11-07 | 2006-03-08 | Trillium Therapeutics Inc. | Methods and compositions for immunomodulation |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| AU2003299823A1 (en) | 2002-12-27 | 2004-07-29 | Schering Corporation | Methods of inducing and maintaining immune tolerance |
| SG10201400426XA (en) | 2006-01-12 | 2014-07-30 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
| AU2008279618B2 (en) | 2007-07-25 | 2014-05-22 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune disease |
| WO2009014745A1 (en) * | 2007-07-25 | 2009-01-29 | Alexion Pharmaceuticals, Inc. | Antibodies to cd200 and uses thereof in inhibiting immune responses |
-
2008
- 2008-07-25 WO PCT/US2008/009037 patent/WO2009014745A1/en not_active Ceased
- 2008-07-25 US US14/080,457 patent/USRE46323E1/en not_active Expired - Fee Related
- 2008-07-25 CA CA2697159A patent/CA2697159C/en not_active Expired - Fee Related
- 2008-07-25 KR KR1020107003921A patent/KR20100041849A/ko not_active Abandoned
- 2008-07-25 AU AU2008279619A patent/AU2008279619B2/en not_active Ceased
- 2008-07-25 JP JP2010518230A patent/JP2010534243A/ja active Pending
- 2008-07-25 US US12/670,379 patent/US8252285B2/en not_active Ceased
- 2008-07-25 MX MX2010000981A patent/MX2010000981A/es active IP Right Grant
- 2008-07-25 BR BRPI0814644-6A2A patent/BRPI0814644A2/pt not_active IP Right Cessation
- 2008-07-25 EP EP08794745A patent/EP2178561A1/en not_active Withdrawn
-
2012
- 2012-06-26 US US13/533,546 patent/US8637014B2/en active Active
-
2013
- 2013-05-27 JP JP2013110577A patent/JP5926702B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-07 JP JP2015135830A patent/JP2015172090A/ja active Pending
-
2016
- 2016-03-16 JP JP2016052050A patent/JP2016117762A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534243A5 (https=) | ||
| JP2015172090A5 (https=) | ||
| JP2009528369A5 (https=) | ||
| Reyes et al. | Intestinal transplantation under tacrolimus monotherapy after perioperative lymphoid depletion with rabbit anti-thymocyte globulin (Thymoglobulin®) | |
| Abu-Elmagd et al. | Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges | |
| Soliman et al. | Short‐term induction therapy with anti‐thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation | |
| Krejci et al. | Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease | |
| JP5926702B2 (ja) | Ｃｄ２００に対する抗体および免疫応答への使用 | |
| JP2014505056A5 (https=) | ||
| Sadaka et al. | Proteasome inhibition for antibody-mediated allograft rejection | |
| Ault et al. | Short-term outcomes of Thymoglobulin induction in pediatric renal transplant recipients | |
| Broeders et al. | Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients. | |
| JP2024534926A5 (https=) | ||
| Chou et al. | Induction immunosuppression with basiliximab in heart transplantation | |
| Pretagostini et al. | Plasmapheresis, photopheresis, and endovenous immunoglobulin in acute antibody-mediated rejection in kidney transplantation | |
| Chuang et al. | Does immunosuppressive pharmacotherapy affect isoagglutinin titers? | |
| Boletis et al. | Delayed renal graft function: the influence of immunosuppression | |
| Anselm et al. | Prolonged basiliximab use as an alternative to calcineurin inhibition to allow renal recovery late after heart transplantation | |
| Sakai et al. | Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient | |
| Baez et al. | Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression | |
| Sulemanjee et al. | The first year post–heart transplantation: Use of immunosuppressive drugs and early complications | |
| Tan et al. | Immunosuppressive preconditioning or induction regimens: evidence to date | |
| Yoshimura et al. | The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using anti-CD20 and anti-CD25 antibody without splenectomy treatment | |
| Kahu et al. | Impact of mycophenolate mofetil intolerance on early results of kidney transplantation | |
| Ferrero et al. | Treatment of acute antibody-mediated rejection: a single-center experience |